Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting
— Anti-PD1-IL-2 BiSKIT (Bi-functional SuperKines for ImmunoTherapy) selectively stimulates anti-cancer immune cells via IL-2 agonism and prevents…